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ABSTRACT 1,2-GG intrastrand cross-links formed in DNA by the enantiomeric complexes [PtCl2(R,R-2,3-diaminobutane
(DAB))] and [PtCl2(S,S-DAB)] were studied by biophysical methods. Molecular modeling revealed that structure of the cross-
links formed at the TGGT sequence was affected by repulsion between the 59-directed methyl group of the DAB ligand and the
methyl group of the 59-thymine of the TGGT fragment. Molecular dynamics simulations of the solvated platinated duplexes and
our recent structural data indicated that the adduct of [PtCl2(R,R-DAB)] alleviated this repulsion by unwinding the TpG step,
whereas the adduct of [PtCl2(S,S-DAB)] avoided the unfavorable methyl-methyl interaction by decreasing the kink angle.
Electrophoretic retardation measurements on DNA duplexes containing 1,2-GG intrastrand cross-links of Pt(R,R-DAB)21 or
Pt(S,S-DAB)21 at a CGGA site showed that in this sequence both enantiomers distorted the double helix to the identical extent
similar to that found previously for the same sequence containing the cross-links of the parent antitumor cis-PtðNH3Þ212
(cisplatin). In addition, the adducts showed similar afﬁnities toward the high-mobility-group box 1 proteins. Hence, whereas the
structural perturbation induced in DNA by 1,2-GG intrastrand cross-links of cisplatin does not depend largely on the bases
ﬂanking the cross-links, the perturbation related to GG cross-linking by bulkier platinum diamine derivatives does.
INTRODUCTION
The activity of the antitumor drug cisplatin (cis-[PtCl2-
(NH3)2]) is related to its binding to DNA. The 1,2-GG
intrastrand cross-links, formed as the major DNA adducts,
are believed to play an important role in the mechanism
underlying antitumor effects of this drug (Jamieson and
Lippard, 1999). The ability to form the 1,2-GG cross-link
as a major lesion has been also observed for a number of
antitumor active analogs of cisplatin in which one or both
NH3 ligands were replaced by primary amine(s) or by
a diamine (Fig. 1). In this class of cytotoxic cisplatin analogs
with a diamine ligand carrying chiral centers, such as
[PtCl2(2,3-diaminobutane (DAB))] or [PtCl2(trans-1,2-
diaminocyclohexane (DACH))] are of a particular interest.
Enantiomeric pairs of these compounds have been shown to
exhibit different biological activities. For example, the R,R
isomer of [PtCl2(DACH)] has somewhat higher antitumor
activity than the S,S isomer (Kidani et al., 1978; Noji et al.,
1981), and the S,S isomer of [PtCl2(DAB)] has been found to
be considerably more mutagenic than the R,R isomer
(Fanizzi et al., 1987). Oxaliplatin, the R,R isomer of
[Pt(oxalate)(DACH)], is currently in clinical use against
metastatic colorectal cancer in which cisplatin is inactive
(Raymond et al., 2002) and produces the same type of inter-
and intrastrand DNA cross-links as cisplatin (Saris et al.,
1996; Woynarowski et al., 2000).
Since DNA is a chiral molecule, the fact that the optical
isomers of platinum diamine complexes differ in their
biological effects is a priori not surprising. The 1,2-GG-Pt
intrastrand cross-link bends generally the DNA double helix
toward the major groove (Jamieson and Lippard, 1999), and
the contacts between the amine ‘‘spectator ligands’’ and the
major groove can affect the adduct structure; the nature of
these contacts would be chirality-dependent. However, con-
vincing evidence for an inﬂuence of such contacts on the
adduct structure has not yet been demonstrated. For instance,
in the crystal structure of a 12-basepair (bp)-long DNA
duplex cross-linked by Pt(R,R-DACH)21 the DACH ligand
forms a hydrogen bond with the O6 atom of the 39-guanine,
and it has been hypothesized that such hydrogen bonding
could explain the differences in biological effects of the R,R
and S,S isomers of [Pt(oxalate)(DACH)] (Spingler et al.,
2001). On the other hand, the molecular structure of the same
12-bp duplex cross-linked with cisplatin is very similar,
showing virtually identical bend and unwinding angles,
although the NH. . .O6 hydrogen bond is not present
(Takahara et al., 1995). Thus, the exact role of the contacts
between the platinum ligands and DNA residues in de-
termining the overall adduct structure is not yet clear.
The recognition and repair of the Pt-DNA cross-links by
cellular proteins is crucial for the processing of these DNA
lesions (Zamble and Lippard, 1999; Stehlikova et al., 2002;
Brabec, 2002). A speciﬁc class of proteins that bind with high
afﬁnity to 1,2-GG adducts of platinum complexes are the
high-mobility-group box (HMGB) proteins (Pil and Lippard,
1992). Vaisman et al. (1999) have investigated the binding
of the ubiquitous HMGB1 protein to duplex DNA containing
an AGGC sequence modiﬁed by different platinum com-
plexes, and found that HMGB1 bound two times more
strongly toDNA cross-linked by cis-PtðNH3Þ212 than toDNA
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cross-linked by Pt(R,R-DACH)21. A similar result was
obtained by Lippard et al. for the isolated A-domain of
HMGB1 (HMGB1a) (Wei et al., 2001). However, when the
afﬁnity to Pt-cross-links within a TGGA sequence was
probed, the HMGB1a domain discriminated by a factor of
.15 between the cis-PtðNH3Þ212 and Pt(R,R-DACH)21 ad-
ducts (Wei et al., 2001). Recently, Malina et al. (2002)
investigated DNA modiﬁed by the two isomers of
[PtCl2(DAB)], a complex closely related to [PtCl2(DACH)]
(Fig. 1)and determined the binding afﬁnities of the two
individual domains of HMGB1protein to Pt(R,R-DAB)21,
Pt(S,S-DAB)21, and cis-PtðNH3Þ212 adducts formed at a
TGGT sequence of a DNA duplex. They found that the
A-domain bound ;2 times more tightly to the Pt(R,R-
DAB)21 adduct than to the cisplatin adduct, whereas the
Pt(S,S-DAB)21 adductwas recognized;8 times less strongly
than the cisplatin adduct. The B-domain of HMGB1
(HMGB1b) also bound more strongly to the Pt(R,R-
DAB)21 adduct than to the Pt(S,S-DAB)21 adduct, but the
difference was less pronounced (Malina et al., 2002). All
these results indicate that the spectator ligands do affect the
recognition of the 1,2-GG platinum cross-link, and that their
inﬂuence is dependent on the nature of the bases ﬂanking GG.
That the differential recognition by HMGB proteins of GG
adducts formed by the enantiomers of the same platinum
complex could originate from structural differences between
the adducts was suggested by another study from the Brabec
group in which the bending and unwinding angles of 20- to
23-bp DNA duplexes cross-linked at a central TGGT
sequence by the R,R and S,S isomers of [PtCl2(DAB)]
were investigated (Malina et al., 2000). The R,R isomer was
shown to bend the double helix by 35 6 2 and to cause an
unwinding of 20 6 2, whereas for the S,S isomer these
values were 24 6 2 and 15 6 3, respectively. Under the
same conditions, the cisplatin adduct formed with the same
sequence bent the DNA helix by 336 2 and unwound it by
156 2 (Stehlikova et al., 2002). In an effort to contribute to
understanding the effect of spectator ligands of platinum
complexes on the structural perturbation of DNA due to the
formation of the 1,2-GG intrastrand cross-links, we used
molecular modeling techniques in this work to investigate
the structures of adducts formed by Pt(R,R-DAB)21, Pt(S,S-
DAB)21, or cis-PtðNH3Þ212 moieties with a 12-bp DNA
duplex including a top strand with a central TGGT sequence
(Scheme 1). The exact sequence of the duplex (designated
subsequently TGGT) corresponded to the inner part of the
duplexes studied previously (Malina et al., 2000). In
addition, we have determined the bending and unwinding
angles induced by 1,2-GG intrastrand cross-links of Pt(R,R-
DAB)21 or Pt(S,S-DAB)21 formed in the duplexes having
a top strand with a CGGA platinum binding site, by means of
gel electrophoretic retardation (phasing) assay. Moreover,
experiments with chemical probes of DNA conformation
were carried out to characterize the distortion caused by
Pt(DAB)21 adducts bound to the CGGA sequence. In
addition, we have probed the recognition of the adducts of
Pt(R,R-DAB)21 and Pt(S,S-DAB)21 with CGGA by the A
and B domains of the HMGB1 protein using the gel elec-
trophoretic mobility-shift assay.
EXPERIMENTAL PROCEDURES
Molecular modeling
The molecular mechanics calculations and molecular dynamics (MD)
simulations used the SANDER module of the program AMBER6.0 (Case
et al., 1999) implemented on a Beowulf cluster of Bi-athlon and Bi-xeon
processors or on a Cray T3E computer. The parm98 force-ﬁeld (Cheatham
et al., 1999) was complemented with parameters describing Pt(II)-
coordination by two guanines, as described previously (Herman et al.,
1990; Elizondo-Riojas et al., 1997; Elizondo-Riojas and Kozelka, 2001).
Density functional theory calculations on the model complex cis-
[Pt(DAB)(1-Me-Guo)2]
21, (B3LYP hybrid functional, LANL2DZ pseu-
doorbital basis set for Pt and 3-21G* for the other atoms) were performed
FIGURE 1 The antitumor compounds cisplatin and oxaliplatin, and the
two enantiomers of [PtCl2(DAB)].
SCHEME 1 Duplex TGGT cross-linked with Pt(DAB)21.
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using the Gaussian98 program, (Frisch et al., 1998) to determine the atomic
charges of the PtðDABÞðdGÞ212 residue, and the Pt-N bond lengths. The MD
simulator used a time step of 2 fs. The electrostatic energy was calculated
using the particle-mesh Ewald method (Darden et al., 1993; Essman et al.,
1995) with a 1-A˚ charge grid, cubic B-spline interpolation and sum tolerance
of 106A˚. During whole MD simulations, Lennard-Jones interactions were
computed with a 9-A˚ cutoff distance, the nonbonded interactions list was
updated every 10 steps, and the SHAKE algorithm (Ryckaert et al., 1977)
was applied to all X-H bonds (tolerance criterion of 0.0005).
The starting structures were generated by adapting the NMR-based
model of an intrastrand cisplatin-GG cross-link by Gelasco and Lippard.
(PDB code 1A84) (Gelasco and Lippard, 1998) to our sequence. The choice
was based on the similarity of the base sequence (the sequences differ only
at positions 1,3, and 4). The Pt(DAB)21 adducts were constructed by
least-squares ﬁtting of the Pt(DAB)21 moiety (obtained from geometry
optimization using B3LYP/Gaussian98) into the cis-PtCl2(NH3)2
21 structure
using the three-atom unit cis-PtN2 as reference. To neutralize the system,
20 sodium counterions were added to solute using the EDIT module of
AMBER6.0; no counterions were placed at the phosphates of the platinated
guanosines. The unit cell used for periodic boundary conditions applied in
each MD simulation was composed of an ;72 3 ;54 3 ;54 A˚
orthorhombic box ramdomlyﬁlledwith 5864 to 5875TIP3Pwatermolecules.
The protocol for energy minimization of starting structures and the
subsequent MD simulations was as described previously (Elizondo-Riojas
and Kozelka, 2001), except that the heating period consisted of two 10-ps
steps, the ﬁrst (0–150 K) with direct temperature scaling, and the second
(150–300K) using the Berendsen algorithm, and the subsequent equilibration
period was extended to 87.5 ps. As previously, three Maxwell redistributions
of velocities (see Supplementary Material, Table S1) were used to attenuate
the inﬂuence of the initial conﬁguration of the system on the dynamics. The
production periods at a constant temperature of 300 K were 2–5 ns long. To
avoid occasional openings of the terminal basepairs, their WC hydrogen
bonds were reinforced bymeans of soft distance constraints of 10 kcal.mol1
A˚2. Table S1 shows the whole MD protocol. The structures having atgt
conformation at the T5-G*6 step were generated by constraining the a and g
torsion angles to 180 with a harmonic constraint (k ¼ 20 kcal.mol1 rad2)
during 67.5 ps at the beginning of the equilibration period, followed by 20 ps
of relaxationwith the torsion constraints removed, and a production period of
2 ns.
One structure was saved every 1 ps during the production period to
constitute the trajectory ﬁle. The analysis of trajectories used the programs
CURVES (Lavery and Sklenar, 1989) for the calculation of helical
parameters (using the ‘‘global’’ helix axis) and the backbone torsion angles,
and the CARNAL module of AMBER6.0 to determine average structures
over the whole production period or for different conformational families.
The averaged structures were submitted to a two-step energy minimization
protocol before structural analysis (500 steps of in vacuo geometry
optimization for hydrogen atoms only, followed by 1000 steps full-energy
minimization using the GBSA module of AMBER6. The program VMD
(Dalke et al., 1997) was used for superposition of molecules, visualiza-
tion, and, coupled to the Raster3D software (Merrit and Bacon, 1997), for
the ﬁgures. The xmgrace program (http://www.caida.org/tools/utilities/
graphing/graph_xmgrace.xml) has been used to plot all graphs.
Materials
[PtCl2(R,R-DAB)] and [PtCl2(S,S-DAB)] were prepared and characterized as
described (Fanizzi et al., 1987). Cisplatin was obtained from Sigma (Prague,
Czech Republic). The stock solutions of platinum compounds were prepared
at the concentration of 5 3 104 M in 10 mM NaClO4 and stored at 4C in
the dark. The synthetic oligodeoxyribonucleotides were synthesized and
puriﬁed as described previously (Brabec et al., 1992). The 20- to 23-bp
oligonucleotide duplexes containing central sequences CGGA/TCCG (for
nucleotide sequences, see Figs. 4–6) uniquely and site-speciﬁcally intrastrand
cross-linked by Pt(R,R-DAB)21, PtCl2(S,S-DAB)
21, or cisplatin were
prepared and characterized as described previously (Malina et al., 2000,
2002). Expression and puriﬁcation of the domains HMGB1a and HMGB1b
were carried out as described (Stros, 2001). T4 DNA ligase and T4
polynucleotide kinase were purchased from New England Biolabs (Beverly,
MA). Acrylamide, bis(acrylamide), urea, and NaCNwere fromMerck KgaA
(Darmstadt, Germany). Dimethyl sulfate, KMnO4, diethyl pyrocarbonate
(DEPC), KBr and KHSO5 were from Sigma (Prague, Czech Republic).
[g-32P]ATP was from Amersham (Arlington Heights, IL). ATP was from
Boehringer (Mannheim, Germany).
Ligation and electrophoresis of oligonucleotides
Details of these experiments were as described in previously published
articles (Bellon and Lippard, 1990; Bellon et al., 1991; Kasparkova et al.,
1996).
Chemical modiﬁcations
The modiﬁcations by KMnO4, DEPC, and KBr/KHSO5 were performed as
described previously (Brabec et al., 1993). The strands of the duplexes were
59-end-labeled with [g-32P]ATP. In the case of the platinated oligonucleo-
tides, the platinum complex was removed after reaction of the DNA with the
probe by incubation with 0.2 M NaCN (pH 11) at 45C for 10 h in the dark.
Electrophoretic mobility shift assays with HMGB1
domain proteins
Radioactively labeled 22-bp DNA probes (10 nM) were titrated with
HMGB1a or HMGB1b proteins in 10-ml sample volumes in the buffer
composed of 10 mM HEPES, pH 7.5, 10 mMMgCl2, 50 mM LiCl, 100 mM
NaCl, 1 mM spermidine, 0.2 mg/ml bovine serum albumin, and 0.05% v/v
Nonidet P40. For all gel mobility shift experiments, samples were incubated
on ice for 1 h and made 7% in sucrose and 0.017% in xylene cyanol before
loading on running, precooled (4C), prerun (300 V, 1–2 h) 5% native
polyacrylamide gels (29:1 acrylamide:bisacrylamide, 0.53 Tris-borate-
EDTA buffer (45 mM Tris-HCl, 45 mM boric acid, and 1 mM EDTA, pH
8.3). Gels were electrophoresed at 4C and 300 V for;1.5 h, dried, exposed
to a molecular imaging plate, analyzed on a Fujiﬁlm bioimaging analyzer,
and the radioactivities associated with bands were quantitated with the
AIDA image analyzer software. Other details have been published pre-
viously (Malina et al., 2002)
RESULTS
Structures of cisplatin adducts with GG
sequences are little affected by ﬂanking bases
An MD simulation of the duplex TGGT cross-linked with
a cis-PtðNH3Þ212 residue, explicitly solvated in a water bath
(see Experimental Procedures) showed features similar to
those seen in a previous simulation of a double-stranded
decamer bearing aGG-Pt cross-linkwithin a CGGA sequence
(Elizondo-Riojas and Kozelka, 2001). Speciﬁcally, we
observed the same lateral movement of the cross-linked GG
dinucleotide with respect to the ﬂanking basepairs, making
the H29 proton of the thymidine 59 to the GG-Pt cross-link
enter and quit the shielding cone of the 59-guanine. The time-
averaged kink angle (626 13) of the cis-PtðNH3Þ212 -TGGT
adduct was similar to that determined previously for the cis-
PtðNH3Þ212 -CGGA adduct (60 6 10) (Elizondo-Riojas and
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Kozelka, 2001). This similarity is in line with the ﬁnding of
Stehlikova et al. (2002) that the bending and unwinding
angles of XGGY sequences bound to cis-PtðNH3Þ212 depend
little on the nature of the bases X and Y.
Structures of Pt(R,R-DAB)21 and Pt(S,S-DAB)21
adducts with TGGT are affected by the repulsion
between the methyl groups of the DAB ligand
and the 59-thymine
Replacing the cis-PtðNH3Þ212 moiety in the time-averaged
structure obtained from the MD simulation of the cisplatin-
TGGT adduct by Pt(R,R-DAB)21 or Pt(S,S-DAB)21 results
in clashes between the 59-directed methyl group of the DAB
ligand and the methyl group of the 59-thymine of the TGGT
tetranucleotide (Fig. 2). From Fig. 2, it appears clear that
neither enantiomer of Pt(DAB)21 bound to a TGGT se-
quence can accommodate the structure preferred by the
cisplatin adduct. Possible ways to avoid this methyl-methyl
repulsion include 1), untwisting or overtwisting the TG step;
2), displacements of the T and G bases along vectors
perpendicular to the helix axis, i.e., modifying the slide and/
or shift; 3), rotations of either base about such vectors, i.e.,
modifying roll and/or tilt; and 4), increasing the rise between
the two bases. The differences in unwinding and kink angles
observed experimentally between the adducts of Pt(R,R-
DAB)21 and Pt(S,S-DAB)21 (Malina et al., 2000) indicated
that the two structures obviate the methyl-methyl clashes dif-
ferently. This is not surprising if one considers the different
positioning of the DAB methyl groups (Fig. 2). It is inter-
esting to note that no clashes are observed between DAB and
thymine methyl groups at the 39-side of the GG-Pt cross-link.
Both Pt(DAB)21 adducts were simulated starting from the
two structures whose details are shown in Fig. 2. In addition,
for both adducts, we considered a variant in which the TpG
step was switched from the canonical ag1 to the atgt
conformation. The atgt conformation has been occasionally
observed in oligonucleotides that are exposed to strain due to
covalent (Sherman et al., 1985) or noncovalent (Djuranovic
and Hartmann, 2003) modiﬁcations and has been reported
to be connected with decreased twist (Djuranovic and
Hartmann, 2003). Therefore, from the experimental observa-
tion that the TGGT adduct with Pt(R,R-DAB)21 unwinds
the double helix more than the adducts of cisplatin or of
Pt(S,S-DAB)21 (Malina et al., 2000; Stehlikova et al., 2002),
one could expect that the Pt(R,R-DAB)21-TGGT adduct un-
winds the TpG step as a reaction to the methyl-methyl repul-
sion, and this unwinding could be stabilized by an ag1/
atgt transition. Such transitions involve relatively high
energy barriers (Varnai et al., 2002) and would not neces-
sarily occur spontaneously during an MD simulation; we
have therefore generated them using dihedral angle con-
straints and simulated the structures with the TpG step
having ag1 and atgt conformations separately. In line with
the expectedly high energy barrier, all four simulations
retained the starting ag1 or atgt conformation.
Table 1 gives the time-averaged values of the twist and roll
angles at the T5-G*6 step as well as the global twist per step
and the global kink angle, as calculated with CURVES
(Lavery and Sklenar, 1989). The extent to which these values
ﬂuctuate during theMD simulation is assessed as the standard
deviation calculated over the ensemble of snapshots. Table 1
shows that the atgt conformation indeed stabilizes smaller
twist and less negative (or positive) roll at the TpG step. As
a consequence, the global twist per step of the two structures
having the atgt conformation is smaller than that of the
structures having a canonical ag1 conformation. The
relationship between the global kink angle and the roll at
the TpG step is less evident (since the global kink depends on
a number of other local parameters), but the negative roll in
the ag1 conformation seems to correlate with the smaller
kink angle observed for these structures. It has to be noted
that the kink values determined for solution structures of
platinated DNA from molecular models are generally ;2
times higher than those obtained from electrophoretic mea-
surements. Possible sources for this discrepancy include
experimental and computational errors, different conditions
in a gel as compared to a diluted solution, and problems in
deﬁning the kink angle (Marzilli et al., 2001; Elizondo-Riojas
and Kozelka, 2001; Spingler et al., 2001). We are concerned
only with relative values here.
The previously reported biophysical measurements (Ma-
lina et al., 2000; Stehlikova et al., 2002), showing that the
Pt(R,R-DAB)21-TGGT adduct unwinds the double helix
more strongly than the cisplatin-TGGT adduct but retains
a similar kink angle, whereas the Pt(S,S-DAB)21-TGGT
adduct kinks the helix axis less but retains similar un-
winding, can be thus plausibly explained by assuming that
the TpG step retains the canonical ag1 conformation in the
FIGURE 2 Detail of the TGGT fragments from the time-averaged,
energy-minimized model of the adduct of cis-PtðNH3Þ212 with duplex
TGGT, where the PtðNH3Þ212 residue was replaced with Pt(R,R-DAB)21
(left) and Pt(S,S-DAB)21 (right), respectively. The methyl groups of the
thymines (blue) and of the DAB ligand (green) are shown as CPK models.
Clash is seen with the 59-thymine but not with the 39-thymine.
4162 Delalande et al.
Biophysical Journal 88(6) 4159–4169
adduct of the S,S isomer but converts to atgt in that of the R,R
isomer. The corresponding models are shown in Fig. 3. The
model that we propose for the Pt(R,R-DAB)21-TGGT
adduct was obtained by time-averaging the structures ob-
served during the simulation ‘‘atgt at T5-G*6’’ (see Table
1); that for the Pt(S,S-DAB)21-TGGT adduct was obtained
similarly from the corresponding simulation ‘‘ag1 at T5-
G*6’’. In Fig. 3, both structures are superimposed with the
model for the cis-PtðNH3Þ212 -TGGT adduct obtained from
the same time-averaging procedure, so that the structural
changes at the T5-G*6 step can be easily seen. To avoid the
clash between the methyl group, the Pt(R,R-DAB)21-TGGT
adduct unwinds the T5-G*6 step, thus increasing the overall
unwinding. On the other hand, the Pt(S,S-DAB)21-TGGT
adduct increases the negative roll of the T5-G*6 step, thus
partially compensating the positive roll of the G*6-G*7 step
and diminishing the overall kink angle.
Hydrogen bonding involving the NH2 groups of
DAB depends only marginally on DAB chirality
It has been suggested previously that stereoselective
hydrogen bonding formed by the amino groups of the
diamine ligand is responsible for the structural differences
between DNA adducts formed by R,R and S,S isomers of
Pt(DAB)21 (Malina et al., 2000) and Pt(DACH)21 (Spingler
et al., 2001) complexes. Table 2 gives time-averaged N. . .O
separations observed during our MD simulations, between
either of the platinum-bound NH2 or NH3 groups and
the proximate O6 atom of the adjacent guanine (G*6 at the
59-side and G*7 at the 39-side), and the O4 atoms of the
next thymine (T5 at the 59-side and T8 at the 39-side).
The distance from the 59-directed NH2 group to the O2 atom
of the phosphate 59 to the GG-Pt cross-link is shown as well.
It can be seen that the average distances characterizing the
hydrogen bonding to the O6 atoms of either platinum-bound
guanine are independent of DAB chirality, and unaffected by
the ag1/ atgt transition. The hydrogen atoms donated by
the 59-directed NH2 group of DAB to the 59-phosphate and to
the O4 atom of the 59-thymine are very slightly dependent on
the DAB chirality (R,R favoring the former and S,S the latter),
and, above all, on the ag conformation. In the canonical
ag1 conformation, the NH2. . .OP hydrogen bond oscillates
between direct bonding and bonding mediated by one water
molecule, whereas in the atgt conformation, there are two
FIGURE 3 TGG fragments of models for the duplex TGGT cross-linked
with Pt(R,R-DAB)21 (red, left) and Pt(S,S-DAB)21 (green, right), both
superimposed with the model for the adduct with cis-PtðNH3Þ212 (blue).
Structures were averaged over the production period of the MD simulations
and subsequently energy-minimized using 1000 cycles of the conjugate-
gradient minimizer of AMBER6.0. The structures were least-squares ﬁtted
using the Pt-G*pG* residue, which is nearly invariant in all three adducts.
The arrows indicate how the two Pt(DAB)21 adducts avoid the methyl-
methyl clash.
TABLE 1 Twist and roll between the bases T5 and G*6, average twist per step and global kink angle, time-averaged
over the MD simulations
Adduct Twist (T5-G*6) Roll (T5-G*6) Average twist Kink
cis-PtðNH3Þ212 -TGGT 31 (68) 10 (66) 31.4 (61.1) 62 (613)
Pt(R,R-DAB)21-TGGT
ag1 at T5-G*6 30 (611) 19 (610) 31.4 (61.1) 59 (614)
DAB equatorial (50%) 30 (611) 18 (610) 31.4 (61.2) 57 (614)
DAB axial (50%) 30 (611) 19 (69) 31.5 (61.0) 61 (613)
atgt at T5-G*6 13 (611) 1 (610) 30.2 (61.3) 66 (614)
DAB equatorial (37%) 15 (610) 1 (69) 30.1 (61.3) 61 (613)
DAB axial (63%) 13 (612) 2 (611) 30.3 (61.3) 69 (614)
Pt(S,S-DAB)21-TGGT
ag1 at T5-G*6 25 (68) 11 (67) 31.0 (61.3) 58 (612)
DAB equatorial (56%) 28 (68) 13 (67) 31.4 (61.2) 57 (613)
DAB axial (44%) 21 (67) 10 (66) 30.5 (61.3) 59 (612)
atgt at T5-G*6 7 (69) 1 (68) 28.8 (61.1) 70 (613)
DAB equatorial (31%) 3 (67) 7 (66) 27.4 (61.2) 80 (69)
DAB axial (69%) 12 (66) 4 (66) 29.5 (61.1) 65 (611)
Standard deviations in parentheses. Values in degrees, all calculated with the ‘‘global’’ helix axis using CURVES (Lavery and Sklenar, 1988).
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intervening water molecules most of the time. Conversely,
the T5O4 atom forms predominantly a direct hydrogen bond
in the atgt conformation, whereas in the ag1 conformation
it oscillates between direct and water-mediated bonding. The
simulations further indicate a short and persistent hydrogen
bond between the 39-directed NH2 group of DAB and the
39-thymine, independently of DAB chirality and ag confor-
mation.
These observations indicate that the previously formulated
hypothesis, that the adduct of Pt(R,R-DAB)21 favors hydro-
gen bonding to the 39-guanine whereas that of Pt(S,S-
DAB)21 instead forms a hydrogen bond with the 59-guanine
(Malina et al., 2000, 2002), is probably incorrect. Our sim-
ulations suggest that both adducts can form both hydrogen
bonds simultaneously. The fact that in the crystal structure of
Pt(R,R-DACH)21, the DACH moiety forms a hydrogen
bond only with the 59-guanine and not with the 39-guanine is
probably due to the considerably smaller kink angle in the
solid state. Although the absolute values of the kink angle
determined by our force-ﬁeld calculations may be over-
estimated, it is very likely that solution structures of Pt-GG
adducts are more severely bent than solid-state structures
(Ano et al., 1999; Marzilli et al., 2001; Elizondo-Riojas and
Kozelka, 2001).
Conformational transitions of the DAB ligands
The ﬁve-membered ring of the Pt(DAB)21 moieties can
assume two stable conformations, one with equatorial
orientations of the methyl groups and another where these
groups are oriented axially. In an isolated [PtL2(DAB)]
complex such as [PtCl2(DAB)], the preferred methyl groups
orientation is expected to be equatorial. However, in a DNA
adduct, interactions with the DNA double helix can affect
such conformational equilibria. In fact, in the simulations of
the Pt(R,R-DAB)21and Pt(S,S-DAB)21 adducts of TGGT,
we observe equatorial-axial transitions (Supplementary
Material, Fig. S1), suggesting that the energies of the two
conformations are similar in the DNA adducts, and that the
barrier is not very high. We checked this using DFT
(B3LYP/3-21*) calculations on the model compound
[Pt(DAB)(NH3)2]
21, for which we found an energy barrier
of 8.7 kcal/mol separating the axial and equatorial DAB
conformations, the latter being favored by 2.4 kcal/mol [J.
Kozelka and O. Delalande, unpublished results]. As can be
seen in Table 1, the twist and roll angles of the T5-G*6 step,
and the global twist and kink angles are to some extent
affected by the equatorial-axial transitions, as expected, since
these transitions modify the position of the DAB methyl
groups, and thus affect the methyl(DAB)-methyl(T) re-
pulsion. The equatorial-axial transitions have, however, no
inﬂuence on the average hydrogen-bonding lengths of the
DAB ligand (Table 2). This conﬁrms our conclusion that the
orientation of the N-H bonds of DAB does not play a signif-
icant role in determining the adduct geometry.
The MD simulations indicate that the differential
responses of the double helix to the chirality
of the Pt(DAB)21 moiety are characteristic
of a TGG sequence
The main conclusion of our MD study is that the different
kink and unwinding angles observed previously for the GG
TABLE 2 Interatomic separations, and their ﬂuctuations, between the two nitrogen atoms of the DAB (or NH3) ligand and
potential hydrogen-bonding acceptors
Adduct N (59). . .T5O4 N (59). . .G*6O6 N (59). . .p6O2 N (39). . .G*7O6 N (39). . .T8O4
cis-PtðNH3Þ212 -TGGT 4.9 (60.8) 4.2 (60.3) 4.3 (61.0) 3.4 (60.2) 3.3 (60.4)
Pt(R,R-DAB)21-TGGT
ag1 at T5-G*6 5.2 (61.0) 3.9 (60.4) 4.6 (61.2) 3.2 (60.2) 3.1 (60.3)
DAB equatorial (50%) 5.4 (61.0) 4.0 (60.3) 4.6 (61.3) 3.3 (60.2) 3.1 (60.2)
DAB axial (50%) 5.0 (61.0) 3.8 (60.4) 4.6 (61.1) 3.2 (60.2) 3.1 (60.3)
Pt(R,R-DAB)21-TGGT
atgt at T5-G*6 3.7 (60.7) 4.0 (60.3) 7.3 (61.3) 3.1 (60.2) 3.2 (60.3)
DAB equatorial (37%) 3.8 (60.7) 4.1 (60.3) 7.2 (61.2) 3.2 (60.2) 3.1 (60.2)
DAB axial (63%) 3.6 (60.7) 4.0 (60.3) 7.4 (61.4) 3.1 (60.1) 3.2 (60.4)
Pt(S,S-DAB)21-TGGT
ag1 at T5-G*6 4.7 (60.8) 3.9 (60.4) 5.1 (61.3) 3.3 (60.2) 3.2 (60.3)
DAB equatorial (56%) 5.0 (60.6) 4.1 (60.3) 4.5 (61.3) 3.3 (60.2) 3.1 (60.3)
DAB axial (44%) 4.3 (60.7) 3.7 (60.4) 5.8 (60.9) 3.3 (60.2) 3.2 (60.3)
Pt(S,S-DAB)21-TGGT
atgt at T5-G*6 3.4 (60.4) 3.7 (60.4) 8.9 (60.9) 3.2 (60.2) 3.2 (60.3)
DAB equatorial (31%) 3.3 (60.3) 3.5 (60.3) 9.6 (60.8) 3.2 (60.2) 3.2 (60.3)
DAB axial (69%) 3.5 (60.5) 3.9 (60.4) 8.6 (60.7) 3.2 (60.2) 3.2 (60.3)
Separation values, given in A˚, were time-averaged over the MD simulations. Fluctuation values are given in parentheses as standard deviations. The
phosphate 59 to G*6 is labeled p6.
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adducts of Pt(R,R-DAB)21and Pt(S,S-DAB)21 (Malina et al.,
2000) are likely to be speciﬁc for sequences TGGN (N¼ any
nucleotide). To check this conclusion, we have determined
experimentally, in the second part of this work, the kink and
unwinding angles of adducts of Pt(R,R-DAB)21and Pt(S,S-
DAB)21 complexes bound to 20- to 23-bp DNA duplexes
similar to those investigated previously (Malina et al., 2000)
but having the inner TGGT-ACCA tetranucleotide replaced
by CGGA-TCCG. These CGGA-containing adducts were
also examined using chemical probes, similarly to the pre-
vious study on the TGGT-containing adducts (Malina et al.,
2000). In addition, since the adducts of Pt(R,R-DAB)21and
Pt(S,S-DAB)21 with the TGGT-sequence were previously
found to be differentially recognized by both domains of
HMGB1, an effect which was attributed to the different kink
and/or unwinding angles of the adducts (Malina et al., 2002),
we have compared the binding of both HMG domains of
HMGB1 to the adducts of Pt(R,R-DAB)21and Pt(S,S-
DAB)21 formed with the CGGA-containing 20-bp duplex,
as described in the following paragraph.
Electrophoretic mobility assays, experiments
with chemical probes, and molecular dynamics
simulations indicate that adducts of
Pt(R,R-DAB)21 and Pt(S,S-DAB)21 with the
CGGA-sequence perturb the double helix in
a way similar to that of cisplatin
As in the previous study (Malina et al., 2000), we used
electrophoretic retardation as a quantitative measure of the
extent of planar curvature to analyze bending and unwinding
induced by the single, site-speciﬁc 1,2-GG intrastrand cross-
link formed by Pt(R,R-DAB)21 and Pt(S,S-DAB)21 in the
sequence CGGA. The oligodeoxyribonucleotide duplexes
CGGA(20–23) (20–23 bp long, whose sequences were
identical or similar to that of the duplex CGGA(21), i.e.,
59-CCTCTCTCCGGATCTCTTCTC/59-GGAGAAGAGA-
TCCGGAGAGAG; the 20-bp duplex had one terminal
CG pair deleted, whereas one additional TA pair was added
to the 39 end in the 22-bp duplex and TA and CG pairs were
added to the 39 end in the 23-bp duplex) were used for the
bending and unwinding studies. The ligation products of
these unplatinated or Pt(DAB)21-containing duplexes were
analyzed on native polyacrylamide electrophoresis gel.
Experimental details of these studies are given in our recent
report (Malina et al., 2000). The results are summarized in
Table 3 and compared to those obtained with the TGGT
sequence (Malina et al., 2000). The DNA bending of 346 2
toward the major groove and unwinding of 20 6 2 due to
the single, site-speciﬁc 1,2-GG intrastrand cross-link formed
by Pt(R,R-DAB)21 or Pt(S,S-DAB)21 at the CGGA se-
quence were identical for both enantiomers. The direction of
the bend was determined using the 33-bp duplex, which also
contained, besides the single 1,2-GG intrastrand cross-link
formed by either Pt-DAB enantiomer in the CGGA
sequence, the (AT)5 tract located ‘‘in phase’’ from the
cross-link (the cross-linked basepair and the center of the A
tract were separated by 11 bp), in the same way as in our
recent articles (Kasparkova et al., 2002, 2003; Loskotova
and Brabec, 1999).
Further studies focused on analysis of the distortion
induced by the 1,2-GG intrastrand cross-link formed by
Pt(R,R-DAB)21 and Pt(S,S-DAB)21 in the sequence CGGA
by chemical probes of DNA conformation. The duplex
CGGA(21) (vide supra) containing a single, site-speciﬁc
cross-link of Pt(R,R-DAB)21 or Pt(S,S-DAB)21 was treated
with several chemical agents used as tools for monitoring the
existence of conformations other than canonical B-DNA.
These agents included KMnO4, bromine, or DEPC as the
probes of thymine, cytosine, or adenine and guanine residues,
respectively. These probes react, under the conditions used,
with base residues in single-stranded DNA and distorted
double-strandedDNA, but not with the base residues in intact,
double-stranded DNA (Bailly et al., 1994; Bailly andWaring,
1997; Brabec et al., 1993; Nielsen, 1990; Ross and Burrows,
1996). For this analysis, we used exactly the same meth-
odology as in our recent studies dealing with DNA adducts of
various antitumor platinum drugs so that the details of this
experiment can be found in those articles (Brabec et al., 1993;
Zehnulova et al., 2001). The results are schematically sum-
marized in Fig. 4 A. The pattern and degree of reactivity
toward the chemical probes was identical for the cross-links
formed by both enantiomers, indicating a similar character of
the conformational distortion. This is in contrast to the results
of the analogous experiments carried out with the duplexes
containing the cross-links in the sequence TGGT (Malina
et al., 2000), where the pattern and degree of reactivity toward
the chemical probes was different for the cross-links of the
two isomers (Fig. 4 B), indicating a chirality-dependent
character of the conformational distortion.
TABLE 3 DNA bending and unwinding induced by the 1,2-GG intrastrand cross-link within the CGGA and TGGT contexts
CGGA TGGT*
cis-PtðNH3Þ212 Pt(R,R-DAB)21 Pt(S,S-DAB)21 cis-PtðNH3Þ212 Pt(R,R-DAB)21 Pt(S,S-DAB)21
Bend angle ()y 34 34 34 33 34 24
Unwinding () 19 20 20 15 20 15
Bending and unwinding were determined by the gel electrophoresis retardation assay.
*TGGT data are taken from Malina et al. (2000).
yBend angle was toward the major groove.
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An additional check of the sequence impact was
accomplished using molecular modeling. The starting struc-
tures that were used for the MD simulations of the adducts of
Pt(R,R-DAB)21 and Pt(S,S-DAB)21 were mutated so that
the platinated TG*G*T sequence became CG*G*A (the new
DNA duplex is subsequently designated CGGA). MD sim-
ulations identical to those of the TGGT adducts were per-
formed with the two CGGA adducts. Indeed, the structures
of both adducts remained similar, with no appreciable diff-
erences at the TpG* step. This is demonstrated in Fig. 5,
which shows a plot of the twist angles. Obviously, the pat-
terns of twist angles observed in the adducts of TGGT are
different, whereas those of the adducts of CGGA are vir-
tually identical.
Neither HMG domain of HMGB1 differentiates
between the 1,2-GG intrastrand adducts of
Pt(R,R-DAB)21 and Pt(S,S-DAB)21 in the
sequence CGGA
We demonstrated in our recent work (Malina et al., 2002)
that different conformations of the 1,2-GG intrastrand
cross-links formed in DNA by Pt(R,R-DAB)21 and Pt(S,S-
DAB)21 are differently recognized by HMG-domain pro-
teins. The domains A and B of HMGB1 protein (HMGB1a
and HMGB1b, respectively) bound to the cross-link of
Pt(R,R-DAB)21 with a considerably higher afﬁnity (;10
times) than to the cross-link of Pt(S,S-DAB)21. In these
experiments, the 20-bp duplex was modiﬁed so that it
contained a single, site-speciﬁc 1,2-GG intrastrand cross-link
of either Pt(R,R-DAB)21 or Pt(S,S-DAB)21 formed at a
central sequence TGGT in the pyrimidine-rich top strand
(shown for HMGB1a in Fig. 6, A and B). Interestingly, the
binding afﬁnity of HMG-domain proteins that speciﬁcally
recognize 1,2-GG intrastrand cross-link to DNA modiﬁed by
cisplatin is modulated by the nature of the base pairs that
immediately ﬂank the platinated d(GpG) site (Dunham and
Lippard, 1997). As the different recognition of the 1,2-GG
intrastrand cross-links formed in DNA by the two enan-
tiomers Pt(R,R-DAB)21 or Pt(S,S-DAB)21 by HMG-domain
proteins was observed for the 1,2-GG intrastrand cross-link
ﬂanked by thymine residues (Malina et al., 2002), it was of
great interest to examine whether HMG-domain proteins
also discriminate between the 1,2-GG intrastrand cross-links
of these enantiomers if the cross-link is ﬂanked by other
bases than two thymines. Hence, in the other experiments we
used the 21-bp duplex, which was modiﬁed so that it con-
tained a single, site-speciﬁc 1,2-GG intrastrand cross-link of
either Pt(R,R-DAB)21 or Pt(S,S-DAB)21 formed at a central
sequence CGGA in the pyrimidine-rich top strand.
HMGB1a and HMGB1b exhibited negligible binding to
the nonmodiﬁed 21-bp duplex CGGA. As indicated by the
presence of a shifted band whose intensity increases with
increasing protein concentration, both HMGB1a and
HMGB1b recognize the duplex containing the 1,2-GG intra-
strand cross-link of either Pt(R,R-DAB)21 or Pt(S,S-DAB)21
(shown for HMGB1a in Fig. 6 C). Since only single-shifted
bands are seen after incubation of the cross-linked CGGA
duplex with either HMGB1a or HMGB1b, detailed titration
studies were possible (the results of the titration of this duplex
containing the 1,2-GG intrastrand cross-link of either Pt(R,R-
DAB)21 or Pt(S,S-DAB)21 with HMGB1a are shown in Fig.
6,C andD). These titration data indicate that HMGB1a binds
the probes containing the cross-link of both Pt(R,R-DAB)21
or Pt(S,S-DAB)21 with a relatively high afﬁnity, which was
similar to that of HMGB1a to the same probe, but containing
FIGURE 5 Twist angles calculated using the ‘‘global axis’’ option of CURVES (Lavery and Sklenar, 1988) for the time-averaged structures from MD
simulations of adducts of duplexes TGGT (left) and CGGA (right).
FIGURE 4 Summary of the reactivity of chemical probes with the
TGGT(21) (left) and CGGA(21) (right) duplexes containing single, site-
speciﬁc 1,2-GG intrastrand cross-link of Pt(R,R-DAB)21 or Pt(S,S-DAB)21.
The reactivity of the chemical probes was evaluated via piperidine-induced
speciﬁc strand cleavage at KMnO4-modiﬁed thymine residues, DEPC-
modiﬁed adenine and guanine residues, and KBr/KHSO5-modiﬁed cytosine
residues. (d) and (s) designate strong or weak reactivity, respectively. The
data for the duplex TGGT were taken from our article published previously
(Malina et al., 2000).
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the cross-link of Pt(R,R-DAB)21 formed in the sequence
TGGT (Fig. 6 A and see Malina et al., 2002). Most inter-
estingly, the afﬁnity of the cross-links formed by both enan-
tiomers in the sequence CGGAwas identical. The titration of
the 22-bp duplex containing the 1,2-GG intrastrand cross-link
of Pt(R,R-DAB)21 or Pt(S,S-DAB)21 formed at the sequence
CGGAwith HMGB1b revealed that this protein also binds to
the intrastrand cross-link of these platinum compounds with
the same afﬁnity although with considerably less afﬁnity
(;30 times) than HMGB1a (not shown).
DISCUSSION
Cross-links between DNA bases and the resulting DNA
distortions are believed to be at the origin of the antitumor
activity of cisplatin and other platinum complexes (Sherman
and Lippard, 1987; Jamieson and Lippard, 1999). An inter-
esting aspect of the structural deformations of DNA caused
by each individual class of cross-links is dependence of these
distortions on the bases ﬂanking the cross-link. As for the
1,2-GG intrastrand cross-link caused by cisplatin as its most
frequent DNA lesion, it has been shown recently that the
most characteristic effects—the bending and unwinding of
the double helix—are very little affected by the bases ﬂank-
ing the cross-link (Stehlikova et al., 2002).
Recently, Malina et al. (2000) found that the bend and
unwinding angles accompanying the 1,2-GG cross-links
formed in the sequence context of TGGT by the chiral
cisplatin analog [PtCl2(DAB)] depend on the chirality of
the asymmetric centers, and that the chirality also affects the
recognition of the lesions by either domain of HMGB1
(Malina et al., 2002). In this work, we found that this struc-
tural differentiation originates from clashes of the 59-oriented
methyl group of the DAB ligand with the methyl group of
the 59-thymine. This discovery implied that this chiral dif-
ferentiation should disappear in sequences XGG with X
being different from T, and we have veriﬁed this prediction
using gel electrophoresis measurements on single, site-
speciﬁc [PtCl2(DAB)] adducts formed in the sequence
CGGA of short oligonucleotide duplexes. Moreover, we
present evidence that both domains of HMGB1 recognize the
Pt(DAB)-GG cross-link within the CGGA sequence with the
same afﬁnity (Fig. 6, C andD), indicating that the differential
protein recognition of the Pt(DAB)-GG cross-links in the
TGGT context is also a result of the clashes between the
methyl groups of the DAB ligand and the 59-thymine.
FIGURE 6 Gel mobility shift assay analysis of the titration of the
duplexes TGGT and CGGA (for sequences, see E) containing the single 1,2-
GG intrastrand cross-link of Pt(R,R-DAB)21 or Pt(S,S-DAB)21 with
HMGB1a protein. (A and C) Autoradiograms of the gel mobility shift
assay of the titration with HMGB1a (0.5 nM–1.4 mM). The concentration of
the duplexes TGGT (A) and CGGA (C) was 10 nM. (B and D) Plots of the
fraction of bound DNA (Q) versus HMGB1a concentration with super-
imposed ﬁts to the equation Q ¼ P/P1 KD(app) (P is the total protein
concentration, and KD(app) is the apparent dissociation constant) (Dunham
and Lippard, 1997; Lohman and Mascotti, 1992). DNA probes were the
duplexes TGGT (B) or CGGA (D) (10 nM) containing the single 1,2-GG
intrastrand CL of Pt(R,R-DAB)21 (n) or Pt(S,S-DAB)21 (d). (E) The
nucleotide sequences of the duplexes TGGT and CGGA used in the
experiments demonstrated in A–D.
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Our results suggest that all platinum ethylenediamine
complexes having a substituent at the carbon centers should
form at the TGG sequences adducts whose structure and
recognition are different from those of adducts at other XGG
sequences. This conclusion is particularly interesting in the
context of previous studies on adducts of the anticancer drug
oxaliplatin ([Pt(oxalate)(R,R-DACH)], see Fig. 1). This drug
is more cytotoxic than its S,S isomer, as concluded from
results with the two enantiomers of its dichloro form (Kidani
et al., 1978; Noji et al., 1981), and this has been explained by
hydrogen bonding between the NH2 groups of the DACH
ligand (whose positions and orientations are chirality-
dependent) and the O6 atoms of the cross-linked guanines
(Malina et al., 2000; Spingler et al., 2001). Since theDAB and
DACH ligands are closely related, our ﬁnding that the
hydrogen bonding from the NH2 groups of DAB are neither
the origin of the different geometries observed for the DNA
adducts of Pt(R,R-DAB)21 and Pt(S,S-DAB)21, nor the cause
of their discrimination by HMGB1, probably applies to
adducts of Pt(DACH)21 as well. Our results to be published
elsewhere (J.Malina andV. Brabec, unpublished data) indeed
conﬁrm that the bend and unwinding angles of theGGadducts
of Pt(DACH)21 at a TGGT sequence are chirality-dependent
in a way similar to the Pt(DAB)21 adducts, whereas at
a CGGA sequence the difference disappears.
Finally, this work demonstrates both the power and the
limits of molecular dynamics simulations. These simulations
allowed us to identify the clashes between the 59-directed
methyl group of DAB and the 59-thymine, and thus to correct
the previous ‘‘hydrogen-bonding hypothesis’’ to explain the
structural differences between TGGT-cross-links formed by
[PtCl2(R,R-DAB)] and [PtCl2(S,S-DAB)] (Malina et al.,
2000). However, it was necessary to use chemical intuition
based on previous structural studies of nucleic acids structure
to manipulate the MD simulations toward the plausible
structural models. Simulations 10–100 times longer would
probably have been needed to observe spontaneous tran-
sitions toward the atgt conformation that seems to stabilize
the adduct of the R,R enantiomer. Also, energy calculation
for the time-averaged structures using the generalized Born
approximation to account for solvent effect did not allow us
to conclude that the adduct of the R,R-enantiomer favors the
ag1/ atgt transition at the TpG step, whereas the adduct
of the S,S enantiomer does not. The successful assignment
of a structural model to each adduct was therefore based on
the comparison between kink and unwinding angles of the
models with those determined experimentally. Thus, both
computational and experimental methods were needed to
explain the structural differences between the GG adducts of
[PtCl2(R,R-DAB)] and [PtCl2(S,S-DAB)], and to conclude
that they are speciﬁc to the TGG sequence.
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